A CRO born from a simple conviction: doing better, more humanely.
A French CRO specialised in biostatistics and data management since 2006. We support academic sponsors, biotechs and pharma companies with proprietary technology solutions.
Nineteen years reinventing rigour
From our first biostatistics assignment to integration into the Oxurion Group.
Axiodis founded
Founded by a team of biostatisticians and data managers from the pharmaceutical industry. First multicentre biostatistics assignments.
Development of Exagis
Launch of our proprietary clinical CDMS. CDISC compliant from the first version, multicentre deployment.
Axiodis becomes a specialist CRO
Strategic repositioning in biostatistics and proprietary technology solutions for academic sponsors, biotechs and pharma.
Acquisition by Oxurion
Integration into the Oxurion Group (Euronext Brussels). Accelerated international development and investment in AI solutions for clinical research.
2006
Axiodis founded
Founded by a team of biostatisticians and data managers from the pharmaceutical industry. First multicentre biostatistics assignments.
2012
Development of Exagis
Launch of our proprietary clinical CDMS. CDISC compliant from the first version, multicentre deployment.
2018
Axiodis becomes a specialist CRO
Strategic repositioning in biostatistics and proprietary technology solutions for academic sponsors, biotechs and pharma.
2025
Acquisition by Oxurion
Integration into the Oxurion Group (Euronext Brussels). Accelerated international development and investment in AI solutions for clinical research.
Three commitments, upheld for 19 years.
Transparency
Detailed pricing, dated deliverables, proactive alerts. You always know exactly where your trial stands.
Excellence
CDISC standards on 100% of studies since 2014. Zero non-conformant FDA audits to date.
Proximity
One dedicated contact per study. Your questions receive an answer in less than 24h, not 2 weeks.
The power of a group, the agility of an expert.
Since 2025, Axiodis CRO is a subsidiary of the Oxurion Group (Euronext Brussels: OXUR). This integration gives us the means to invest in R&D — particularly in AI applied to clinical data (digital twins, automated quality control) — while preserving our human-scale approach and operational independence.
Ready to start your study?
Tell us about your project. We will respond within 24h with a methodological and budgetary framework — no commitment required.